EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Ioana Agache; Cezmi Akdis; Mubeccel Akdis; Knut Brockow; Tomas Chivato; Stefano Del Giacco; Thomas Eiwegger; Kilian Eyerich; Ana Giménez-Arnau; Jan Gutermuth; Emma Guttman-Yassky; Marcus Maurer; Graham Ogg; Peck Y Ong; Liam O'Mahony; Jürgen Schwarze; Amena Warner; Thomas Werfel; Oscar Palomares; Marek Jutel

doi:10.1111/all.15030

EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Ioana Agache, Cezmi Akdis, Mubeccel Akdis, Knut Brockow, Tomas Chivato, Stefano Del Giacco, Thomas Eiwegger, Kilian Eyerich, Ana Giménez-Arnau, Jan Gutermuth, Emma Guttman-Yassky, Marcus Maurer, Graham Ogg, Peck Y Ong, Liam O'Mahony, Jürgen Schwarze, Amena Warner, Thomas Werfel, Oscar Palomares, Marek Jutel

Onderzoeksoutput: Article › peer review

32 Citaten (Scopus)

Samenvatting

Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

Originele taal-2	English
Pagina's (van-tot)	17-38
Aantal pagina's	22
Tijdschrift	Allergy
Volume	77
Nummer van het tijdschrift	1
Vroegere onlinedatum	29 jul 2021
DOI's	https://doi.org/10.1111/all.15030
Status	Published - jan 2022

Bibliografische nota

Toegang tot document

10.1111/all.15030

Andere bestanden en links

Link to publication in Scopus

Citeer dit

Agache, I., Akdis, C., Akdis, M., Brockow, K., Chivato, T., Del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O'Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., & Jutel, M. (2022). EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy, 77(1), 17-38. https://doi.org/10.1111/all.15030

Agache, Ioana ; Akdis, Cezmi ; Akdis, Mubeccel ; Brockow, Knut ; Chivato, Tomas ; Del Giacco, Stefano ; Eiwegger, Thomas ; Eyerich, Kilian ; Giménez-Arnau, Ana ; Gutermuth, Jan ; Guttman-Yassky, Emma ; Maurer, Marcus ; Ogg, Graham ; Ong, Peck Y ; O'Mahony, Liam ; Schwarze, Jürgen ; Warner, Amena ; Werfel, Thomas ; Palomares, Oscar ; Jutel, Marek. / EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. In: Allergy. 2022 ; Vol. 77, Nr. 1. blz. 17-38.

@article{4061f4f4dd5545e788762a64a09ce4a8,

title = "EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old",

abstract = "Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.",

keywords = "GRADE, chronic spontaneous urticaria, guidelines, omalizumab",

author = "Ioana Agache and Cezmi Akdis and Mubeccel Akdis and Knut Brockow and Tomas Chivato and {Del Giacco}, Stefano and Thomas Eiwegger and Kilian Eyerich and Ana Gim{\'e}nez-Arnau and Jan Gutermuth and Emma Guttman-Yassky and Marcus Maurer and Graham Ogg and Ong, {Peck Y} and Liam O'Mahony and J{\"u}rgen Schwarze and Amena Warner and Thomas Werfel and Oscar Palomares and Marek Jutel",

note = "{\textcopyright} 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",

year = "2022",

month = jan,

doi = "10.1111/all.15030",

language = "English",

volume = "77",

pages = "17--38",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "1",

}

Agache, I, Akdis, C, Akdis, M, Brockow, K, Chivato, T, Del Giacco, S, Eiwegger, T, Eyerich, K, Giménez-Arnau, A, Gutermuth, J, Guttman-Yassky, E, Maurer, M, Ogg, G, Ong, PY, O'Mahony, L, Schwarze, J, Warner, A, Werfel, T, Palomares, O & Jutel, M 2022, 'EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old', Allergy, vol. 77, nr. 1, blz. 17-38. https://doi.org/10.1111/all.15030

EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. / Agache, Ioana; Akdis, Cezmi; Akdis, Mubeccel; Brockow, Knut; Chivato, Tomas; Del Giacco, Stefano; Eiwegger, Thomas; Eyerich, Kilian; Giménez-Arnau, Ana; Gutermuth, Jan; Guttman-Yassky, Emma; Maurer, Marcus; Ogg, Graham; Ong, Peck Y; O'Mahony, Liam; Schwarze, Jürgen; Warner, Amena; Werfel, Thomas; Palomares, Oscar; Jutel, Marek.

In: Allergy, Vol. 77, Nr. 1, 01.2022, blz. 17-38.

Onderzoeksoutput: Article › peer review

TY - JOUR

T1 - EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

AU - Agache, Ioana

AU - Akdis, Cezmi

AU - Akdis, Mubeccel

AU - Brockow, Knut

AU - Chivato, Tomas

AU - Del Giacco, Stefano

AU - Eiwegger, Thomas

AU - Eyerich, Kilian

AU - Giménez-Arnau, Ana

AU - Gutermuth, Jan

AU - Guttman-Yassky, Emma

AU - Maurer, Marcus

AU - Ogg, Graham

AU - Ong, Peck Y

AU - O'Mahony, Liam

AU - Schwarze, Jürgen

AU - Warner, Amena

AU - Werfel, Thomas

AU - Palomares, Oscar

AU - Jutel, Marek

PY - 2022/1

Y1 - 2022/1

N2 - Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

AB - Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

KW - GRADE

KW - chronic spontaneous urticaria

KW - guidelines

KW - omalizumab

UR - http://www.scopus.com/inward/record.url?scp=85112064104&partnerID=8YFLogxK

U2 - 10.1111/all.15030

DO - 10.1111/all.15030

M3 - Article

C2 - 34324716

VL - 77

SP - 17

EP - 38

JO - Allergy

JF - Allergy

SN - 0105-4538

IS - 1

ER -